Emerging Therapies In Respiratory Diseases

Question 1

Traditional Hurdles of new medicines

Answer 1

Safety
Quality
Efficacy
Clinical cost effectiveness
Affordability and impact on services
Appropriateness

Question 2

Do we really need
new therapies?

Answer 2

There are needs and constraints - drives and drags

DRIVE: Unmet clinical need
Scientific progress
Commercial factors

DRAG:
Healthcare providers
Generics
Rationing
Pricing policy

Question 3

Asthma Impacts

Answer 3

400M sufferers worldwide by 2025

High incidence in USA, UK,
Australia, New Zealand

Growing incidence in BRICs

Pharmaceutical market US$22bn in
2019

Asthma attacks/exacerbations:
Intense breathlessness
Distressing
Potentially fatal

High and skewed impact on resources: 5-10% patients account for 50% asthma costs